

Tykerb® 250mg指定批次產品回收公告

Aug 31, 2026

諾華香港現正就指定批次的 Tykerb® (lapatinib) 250mg 進行自願回收。原因為例行檢測中發現相關情況。

受影響產品

- 產品名稱：Tykerb® 250毫克（70粒裝）
- 批號：RD0944
- 有效日期：2029年2月28日

是次回收僅涉及上述批次產品。

持有或正在服用受影響批次產品的病人不應自行停藥，應盡早向其醫護人員諮詢意見，以作適當安排。

如對是次回收有任何查詢，請聯絡諾華香港
查詢熱線：8203 6077

諾華將繼續致力維持產品品質及病人安全。

有關香港藥物回收的更多資訊，請瀏覽衛生署藥物辦公室網站：[藥物回收資訊](#)。

免責聲明：本公告僅供參考，並不可取替求醫的需要，亦不能作為自我診斷或醫療決定的依據。唯有您的醫生方能為您作出準確的診斷及提供適當的治療。如對個別疾病有任何問題，請諮詢您的醫生的專業意見。

FA-11777045 Aug 2026

Recall of One Batch of Tykerb® 250 mg

Novartis Hong Kong is conducting a voluntary recall of one batch of Tykerb® (lapatinib) 250mg following a finding identified during routine testing.

Affected product

- Product: Tykerb® 250 mg (70 tablets)
- Batch Number: RD0944
- Expiry Date: 28 February 2029

This recall applies only to the batch specified above.

Patients who have received or are taking the affected batch should not stop taking the medicine but should seek advice from their healthcare professionals as soon as possible for appropriate arrangements.

For enquiries regarding this recall, please contact the Novartis Hong Kong hotline:
Tel: +852 8203 6077

Novartis remains committed to maintaining high standards of product quality and patient safety.

For more information on medicine recalls in Hong Kong, please visit the Department of Health Drug Office's Medicines Recalls webpage.

Disclaimers: This notice is for general reference only. It cannot be used in place of a consultation with a healthcare professional nor as a basis of self-diagnosis or for medical treatment decision. Only your physician can provide you with accurate diagnosis and appropriate treatment. In case of any questions relating to any disease, please consult your physician for professional advice.

FA-11777045 Aug 2026

Source URL:

<https://www.novartis.com/hk-zh/news/media-releases/tykerb-250mgzhidingpicichanpinhuishougonggao>

List of links present in page

- <https://www.novartis.com/hk-zh/hk-zh/news/media-releases/tykerb-250mgzhidingpicichanpinhuishougonggao>
- <https://www.drugoffice.gov.hk/eps/news/showNews/Tykerb+Tablets+/pharmaceuticaltrade/2026-08-28/tc/58042.html?nstone=7SOY%2FFbMog3%2FTQb%2FKItK4%2FIOD8jf7hd5HIW8itDchbgHkThOMV%2F%2Bf9OfldJ1%2F3qCkU%2B05t3wMfoao%2FU%2FKTbPwuCHfloGr3H0eZNTZ%2F7VTA8KjtzzbK%2FZMQX8YHQiax3hQaK%2BhAZ0%2BIMNLFsrs3EDDSpd>

C89CULe8TS5G%2F2%2Fg8IQNrIFpK9hR1JQqzMhxWdbFwxZz1XZGYADsrWU5pUFmP%
2BS4Aatb6W0kPhcL%2FkdfH2SuAzuEixkcmK3K41%2FjIGJwTaqpVxtTNn54unzJ2Mm8OL%
2F3yqVZfLfnCsKngeAPaST6Xv%2F8%2FroIKeF8l1Ulro7arWqwxSEUkRO8cs6N1%2FIZaTV
Ju8M7%2Fd%2BW7wIPZaGkkCNuZsn1pnyYRyvyi%2BeHK%2BWbIPmGA99NDFeyDmqt4P
o9C1Rvk9efw5rp0Va1cNIDydp%2BNi%2BG69Hw0YFUfNyqd8Uw0vLocd1pXFqD8%2Fv6K1
OtZVYFKXftWhNMSGFORJsalsint78ogsdS6IRsxc2k0kqpupFhOmfVjkfQUL42xuiqltxog4d1uyN
1NhoiuFGtFGRvluA5brF2r9zrz6j6syP0CKeieb9z13Ofc4YeBjCppl8Q1lci5BBGI8EAUTICn98
6eESpGFbKg6jngNeOYjzHb%2FN3ZqY6p9Wowe3A2%2BV%2B6VhCC3yH400bQLf%2BCt
D3Zjzg49Ad%2FqqlyA%3D%3D&nscheck=FHjz9hdecNV87bmp9SU2%2BQ%3D%3D

- <https://www.drugoffice.gov.hk/eps/news/showNews/Tykerb+Tablets+/pharmaceuticaltrade/2026-08-28/en/58042.html?nstoken=7SOY%2FFbMog3%2FTQb%2FKItK4%2FIOD8jf7hd5HIW8itDchbgHkThOMV%2F%2Bf9OfldJ1%2F3qCkU%2B05t3wMfoao%2FU%2FKTbPwuCHfloGr3H0eZNTZ%2F7VTA8KjtzzbK%2FZMQX8YHQiax3hQaK%2BhAZ0%2BIMNLFsrs3EDDSpdC89CULe8TS5G%2F2%2Fg8IQNrIFpK9hR1JQqzMhxWdbFwxZz1XZGYADsrWU5pUFmP%2BS4Aatb6W0kPhcL%2FkdfH2SuAzuEixkcmK3K41%2FjIGJwTaqpVxtTNn54unzJ2Mm8OL%2F3yqVZfLfnCsKngeAPaST6Xv%2F8%2FroIKeF8l1Ulro7arWqwxSEUkRO8cs6N1%2FIZaTVJu8M7%2Fd%2BW7wIPZaGkkCNuZsn1pnyYRyvyi%2BeHK%2BWbIPmGA99NDFeyDmqt4Po9C1Rvk9efw5rp0Va1cNIDydp%2BNi%2BG69Hw0YFUfNyqd8Uw0vLocd1pXFqD8%2Fv6K1OtZVYFKXftWhNMSGFORJsalsint78ogsdS6IRsxc2k0kqpupFhOmfVjkfQUL42xuiqltxog4d1uyN1NhoiuFGtFGRvluA5brF2r9zrz6j6syP0CKeieb9z13Ofc4YeBjCppl8Q1lci5BBGI8EAUTICn986eESpGFbKg6jngNeOYjzHb%2FN3ZqY6p9Wowe3A2%2BV%2B6VhCC3yH400bQLf%2BCtD3Zjzg49Ad%2FqqlyA%3D%3D&nscheck=FHjz9hdecNV87bmp9SU2%2BQ%3D%3D>